Cordyceps sinensis strain CS-100 and use thereof in treating or preventing abnormal QN1 protein related diseases and in promoting nerve cell growth

摘要

#$%^&*AU2019101450A420200402.pdf#####ABSTRACT OF THE DISCLOSURE The present invention discloses a novel Cordyceps sinensis strain CS-100, deposited on July 7, 2018 in China General Microbiological Culture Collection Center under 5 CGMCC Accession Number 14350. The Cordyceps sinensis strain CS-100 can effectively and specifically inhibit the accumulation ofQN1proteinin nerve cells and promote the synaptic regeneration, thereby achieving an efficacy of treating or ameliorating diseases associated with 10 abnormal QN1 protein and neurodegenerative diseases.